SCHEDULE: FMR LLC Reports 1.4% Stake in Tenax Therapeutics

FMR LLC and Abigail P. Johnson have jointly filed an amended Schedule 13G, disclosing beneficial ownership of 1.4% of Tenax Therapeutics Inc.'s common stock as of August 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed an amendment to their Schedule 13G filing.
• As of August 31, 2026, FMR LLC and Abigail P. Johnson collectively beneficially own 514,925 shares of Tenax Therapeutics Inc. common stock.
• This represents 1.4% of the total outstanding common stock.
• FMR LLC is classified as a holding company (HC), and Abigail P. Johnson is classified as an investment company (IN).
• The filing indicates that no single other person holds more than 5% of the common stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on beneficial ownership rather than a significant operational or financial disclosure.

Positives

• Disclosure of significant institutional ownership can sometimes signal confidence in the company's future prospects.
• The filing confirms a stable ownership structure with no single entity holding a dominant stake, which can be seen as a positive for broad shareholder representation.

Negatives

• The filing does not contain any financial performance data or operational updates, limiting its insight into the company's current health.
• The ownership stake is relatively small (1.4%), suggesting FMR LLC and Abigail P. Johnson are not currently seeking to exert significant control or influence over the company.

Risks

• The filing does not explicitly mention any risks.
• However, the limited ownership percentage could imply a lack of strong conviction from these investors, which could be a subtle indicator of underlying concerns not detailed in this specific filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. This filing indicates FMR LLC and Abigail P. Johnson's investment in Tenax Therapeutics, a biotechnology company, aligns with broader investment trends in the healthcare and life sciences sectors.

Comparison to Industry Standards

• This filing is a regulatory disclosure and does not contain performance metrics for comparison against industry standards.
• The 1.4% ownership stake is a common threshold for initial reporting under Schedule 13G for large investment firms.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional investor's stake, which can influence market perception.
• Management: The disclosure confirms FMR LLC and Abigail P. Johnson's passive investment approach, indicating no immediate intent to influence corporate control.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to monitor their investment in Tenax Therapeutics.
• Further filings will be made if ownership levels change significantly.

Key Dates

Keywords

Tenax Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Investment Company, Holding Company